Sentences with phrase «for diabetes development»

Not exact matches

Mannkind, which focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, entered a shallow but persistent downtrend in 2004, posting a series of lower highs into 2015.

Excessive inflammation and oxidative stress are risk factors not only for the development of chronic diseases like type 2 diabetes, but also for the development of cancers.

As maladies of plenty such as obesity, diabetes and heart disease afflict the developed world, and elite pro sports reek of excess, SDP is a sobering counterpoint, spreading health messages, pacifying communities in conflict, preparing refugees for resettlement and providing what experts consider the simplest means of promoting development: improved status for women.

According to Dr. Anita Swamy, Medical Director at he Chicago Children's Diabetes CEnter at La Rabida, there is a strong link between PCOS and diabetes: «While type 2 diabetes risk factors such as insulin resistance and glucose intolerance are often seen in patients with PCOS, PCOS itself confers a significant risk, up to 10-fold versus the normal population, for development of type 2 diabetesDiabetes CEnter at La Rabida, there is a strong link between PCOS and diabetes: «While type 2 diabetes risk factors such as insulin resistance and glucose intolerance are often seen in patients with PCOS, PCOS itself confers a significant risk, up to 10-fold versus the normal population, for development of type 2 diabetesdiabetes: «While type 2 diabetes risk factors such as insulin resistance and glucose intolerance are often seen in patients with PCOS, PCOS itself confers a significant risk, up to 10-fold versus the normal population, for development of type 2 diabetesdiabetes risk factors such as insulin resistance and glucose intolerance are often seen in patients with PCOS, PCOS itself confers a significant risk, up to 10-fold versus the normal population, for development of type 2 diabetesdiabetes.»

For all newborns, breast milk helps protect them from infection, aids their cognitive development and seems to reduce the chances of obesity, diabetes and hypertension later in life.

This avoided formula milk among this group of babies during the early feeding stage, which the authors suggest may have long term implications for future development of diabetes in these infants.

Not being breastfed can disrupt optimal growth and development, especially in the first two years, when the key components of the immune system are forming to protect the child for life from chronic illnesses such as diabetes, cancer, and autoimmune diseases.

There is NO nutritional value in this formula and the white sugar will harm future bone and teeth development as well... not to mention increasing the risk for diabetes!

It is unacceptable for people with diabetes to be deprived of (new) developments because of «postcode prescribing» where access to treatment depends on where the individual lives or from whom they receive their diabetes care..

They were reexamined every two or three years to check for the development of Type 2 diabetes, and their medical records also were reviewed.

Manufacturing small proteins known as peptides is usually very time - consuming, which has slowed development of new peptide drugs for diseases such as cancer, diabetes, and bacterial infections.

It is highly associated with obesity and diabetes, and is one of the reasons for concern over the increasing rates of both problems in the U.S. NASH can lead to cirrhosis and to hepatocellular carcinoma (liver cancer), so understanding its development is becoming more and more important.

The saliva of the Gila monster lizard provided the inspiration for the development of exenatide, which has been used since 2005 to treat Type 2 diabetes.

The report indicates that Sestrin 3 plays a critical role in regulating molecular pathways that control the production of glucose and insulin sensitivity in the liver, making it a logical target for drug development for type 2 diabetes and metabolic syndrome, which can produce increased blood pressure, abnormal cholesterol levels and insulin resistance.

A search of the CRISP database of NIH - funded research projects on three key words — mutant, androgen, and receptor — yields 24 projects funded since 1999 by nine different NIH institutes: the National Cancer Institute (eight projects), the National Institute of General Medical Sciences (NIGMS, three projects), the National Institute of Child Health and Human Development (three projects), the National Institute of Diabetes and Digestive and Kidney Diseases (two projects), and the National Center for Research Resources (two projects).

The role of Apelin and Elabela in establishing the circulatory system makes them potential targets in future development of therapeutic applications for illnesses ranging from the various cancers, and cardiovascular diseases, to even metabolic diseases such as diabetes.

«This would aid the development of the next generation of treatments as well as combination therapies for Type 2 diabetes.»

«Our discovery is essential to understand the mechanisms responsible for the development of type 2 diabetes, which occurs generally in adults and is often associated with weight gain.

This group's achievement will lead to the clarification of the mechanism behind the localization of GLUT4 and the mechanism for developing diabetes, as well as the development of new types of treatment drugs.

For the authors, «this research is further evidence of the undeniable role microbiota plays in autoimmune diseases, particularly in controlling the development of autoimmune diabetes.»

These are all key risk factors for the development of metabolic diseases, such as obesity, type 2 diabetes and cardiovascular disease.

More concerning, niacin was associated with an increased trend toward death from all causes as well as significant increases in serious side effects: liver problems, excess infections, excess bleeding, gout, loss of control of blood sugar for diabetics and the development of diabetes in people who didn't have it when the study began.

This study also considers the distinct paths of diabetes development compared with previous studies which have predominantly used «full blown» diabetes as the measure of progression for the condition.

Researchers from Inserm, Paris Descartes University and the CNRS (French National Centre for Scientific Research), through collaboration with teams from China and Sweden, have recently shown how microbiota protects against the development of type 1 diabetes.

Studies have shown that, for some people, changes in blood concentrations of osteocalcin may even stave off the development of diabetes.

Exposing infants and children to higher amounts of sugar during growth and development can produce problems with cognitive development and learning as well as create lifelong risk for obesity, diabetes, fatty liver disease and heart disease, said Goran, founding director of the Childhood Obesity Research Center at the Keck School of Medicine.

Each participant was enrolled at infancy, between 2004 and 2010, and followed in 3 to 6 months intervals for 10 years to track any development of islet autoantibodies and subsequent type 1 diabetes.

The NUCKS protein is an important clue for controlling diabetes development in obese individuals.

Their research, funded by the Swiss National Science Foundation (SNSF), shows that perturbations of this machinery might be important for type 2 diabetes development.

Raydiance's technology has attracted the attention of the U.S. Food and Drug Administration (FDA), which in July 2007 signed the company to a two - year cooperative research and development agreement that has allowed the FDA's Center for Devices and Radiological Health (CDRH) to evaluate the use, safety and effectiveness of Raydiance's USP laser system in a number of areas, including the ablation of corneal tissues in refractive surgery and corneal repair; the administration of light therapy for treating cancer, cardiovascular disease and diabetes; and the removal of plaque on teeth without damaging the enamel.

«The Action Plan targets, including a 25 % relative reduction in the overall mortality of men and women aged between 30 and 70 years from cardiovascular diseases, cancer, diabetes or chronic respiratory diseases, should be a priority for all public health and development partners,» Chestnov said.

The finding, published in the journal Developmental Cell, opens up new possibilities for the development of drugs that block MCRS1 to treat cancer and diabetes.

We believe that this new information on the structure of the adiponectin receptors will help us understand new relationships between the structure and functions of these important receptors, which we know to be evolutionarily conserved, and hopefully will contribute to the development of new adiponectin receptor agonists that can be used for the treatment of obesity - related diseases such as type 2 diabetes.

«We know from previous human studies that changes in gut bacterial composition correlate with the early development of type 1 diabetes, and that the interactions between bacterial networks may be a contributing factor in why some people at risk for the disease develop type 1 diabetes and others don't,» said Jessica Dunne, Director of Discovery Research at JDRF, which funded the study.

A diet high in saturated fat results in chronic low - grade inflammation in the body that in turn leads to the development of metabolic syndrome, a serious condition associated with cognitive dysfunction and dementia as well as being a major risk factor for cardiovascular disease and type 2 diabetes.

But he adds that for people with «sedentary» diseases such as obesity or diabetes, the drugs are an exciting development.

The basic premise of the work looks solid, says Juan Dominguez - Bendala, director of stem cell development for Translational Research at the University of Miami Miller School of Medicine's Diabetes Research Institute in Florida.

Solt notes that the study strongly suggests that Th17 cells have a pathological role in the development of type 1 diabetes and use of ROR - specific synthetic compounds targeting this cell type may have potential as a preventative therapy for type 1 diabetes.

IPMNs can be characterized as either low - or high - risk for the development of pancreatic cancer; however, the only way to accurately characterize the severity of IPMNs is by their surgical removal that is in itself associated with a risk of complications, such as long - term diabetes and death.

A distinct approach to develop liposomes useful for treatment of diabetes is under development with Boise State biology professor Denise Wingett.

For a long time it has been known that the protein TOR — Target of Rapamycin — controls cell growth and is involved in the development of diseases such as cancer and diabetes.

Genetic cause found for loss of beta cells during diabetes development Worldwide, 400 million people live with diabetes, with rapid increases projected.

Funding support for this research came, in part, from the National Institutes of Health (grants DK - 033651, DK - 074868, DK - 063491 and P01 - DK054441), the American Diabetes Association, the National Institute of Aging and National Institute of Child Health and Human Development (grants R01AG43120 and R24HD050837) and the Wellcome Trust.

The company's lead PEC - DirectTM product candidate is entering clinical development as a potential functional cure for patients with type 1 diabetes with the highest risk of life threatening acute complications.

Funding for the study came from grants HL071981, DK091718, HL073168, DK046200 (Boston Obesity Nutrition Research Center), and DK36836 (Genetics Core of the Diabetes Research Center at Joslin Diabetes Center) from the National Institutes of Health, an American Heart Association Scientist Development Award (0730094N), a grant from the Italian Ministry of Health («Ricerca Corrente 2011 e 2012»), and a grant from Fondazione Roma («Sostegno alla ricerca scientifica biomedica 2008»).

Current applications include studies related to carbon sequestration, as well as the development of biomarkers for breast and brain cancer, neurological diseases, and diabetes and kidney diseases, among others.

Zucara Therapeutics, a spin - off company by The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI), is developing the first drug therapy to prevent hypoglycemia in people with diabetes.

Gladstone investigators also discovered that the p75 neurotrophin receptor — a protein long known for its role in the development of brain cells — plays unexpected roles in metabolic disorders, such as type 2 diabetes.

The PEC - Encap ™ (also known as VC - 01) product candidate is designed to deliver the same pancreatic progenitor cells in an immunoprotective device and is currently in active development as a therapy for all patients with type 1 diabetes as well as insulin requiring patients with type 2 disease.

Dr. Laikind will review recent progress with the company's VC - 01 ™ islet replacement product candidate for the treatment of type 1 diabetes, which recently entered the clinical phase of development.